AbCellera BiologicsvsMerck & Company

ABCL and MRK stock compared: price, dividend, valuation and results, from SEC filings.

ABCL

AbCellera Biologics Inc.

$11.12

Value $3.6B

-3.22%
ABCL's page

MRK

Merck & Company, Inc.

$144.46

Value $357B

-2.23%
MRK's page

AbCellera Biologics (ABCL) has a market value of $3.6B and Merck & Company (MRK) $357B. Over the last year, with dividends, ABCL moved +201.4% and MRK +60.0%. Dividend yield: ABCL none, MRK 2.35%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    ABCL$3.6B

    MRK$357B

    MRK is 98 times ABCL

  • Revenue, 12 months

    ABCL$68M

    MRK$67.4B

    MRK is 993 times ABCL

  • Net income, 12 months

    ABCL-$148M

    MRK$2.5B

  • Operating margin

    ABCL-298.0%

    MRK–

  • ROIC

    ABCL-16.5%

    MRK3.9%

    20.4 points apart

  • P/E

    ABCL–

    MRK145.6

  • Dividend yield

    ABCL0.0%

    MRK2.4%

    2.4 points apart

  • 5-year return

    ABCL-32.2%

    MRK+101.1%

    133.3 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

ABCL-32.2%

MRK+101.1%

010020020222023202420252026
Returns by period
PeriodABCLWith dividendsMRKWith dividends
1 year since November 14, 2025+201.4%Price +201.4%+60.0%Price +55.5%
3 years since November 16, 2023+153.9%+36.4% a yearPrice +153.9%+55.2%+15.8% a yearPrice +41.6%
5 years since November 15, 2021-32.2%-7.5% a yearPrice -32.2%+101.1%+15.0% a yearPrice +72.6%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

ABCLAbCellera BiologicsMRKMerck & Company

Valuation

ABCLMRK
Valuation
Price$11.12$144.46
Market value$3.6B$357B
Enterprise value (EV)$2.9B$401B
P/E–145.6
P/E, 5-year median–14.8
P/B3.48.0
EV/EBIT–84.3
Free cash flow yield–4.1%

Results and growth

ABCLMRK
Results and growth
Revenue, 12 months$68M$67.4B
Net income, 12 months-$148M$2.5B
Free cash flow, 12 months-$33M$14.7B
Earnings per share, 12 months-$0.48$0.98
Revenue growth, year on year160.6%1.3%
Revenue growth a year, past-20.3%over 5 years+9.4%over 5 years
EPS growth a year, past–+21.2%over 5 years

Margins and returns on capital

ABCLMRK
Margins and returns on capital
Gross margin–71.8%
Operating margin-298.0%–
Net margin-218.5%3.6%
ROIC-16.5%3.9%
ROE-15.4%5.2%

Balance sheet

ABCLMRK
Balance sheet
Cash$764M$9.7B
Total debt$134M$53.8B
Net debt / EBITDA–5.7
Interest cover–2.4×

Dividends and buybacks

ABCLMRK
Dividends and buybacks
Dividend yield–2.4%
Dividend per share, 12 months–$3.40
Dividend growth a year, past–+5.8%over 5 years
Buyback yield–1.4%
Shareholder yield–3.8%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: ABCL or MRK

Didn't find what you were looking for?

Ask us
Which is bigger, AbCellera Biologics or Merck & Company?

By market value, Merck & Company ($357B) is about 98.3 times AbCellera Biologics ($3.6B), at today's prices.

How did ABCL and MRK stock do over the last 5 years?

Since November 15, 2021, ABCL's price moved -32.2% and MRK's +72.6%. With dividends: ABCL -32.2% (-7.5% a year), MRK +101.1% (+15.0% a year). Past returns do not predict future ones.

Which pays the higher dividend, ABCL or MRK?

The dividend yield at today's price is none for AbCellera Biologics and 2.35% for Merck & Company. Over the last twelve months they paid – and $3.40 per share.

Which has the higher profit margins, AbCellera Biologics or Merck & Company?

Over the last twelve months, the net margin was -218.5% for AbCellera Biologics and 3.6% for Merck & Company, and the operating margin -298.0% and –. Revenue was $68M and $67.4B.

Which is the better investment, AbCellera Biologics or Merck & Company?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.